Literature DB >> 9779380

Mycobacteria as pathogens of respiratory infection.

D E Griffith1.   

Abstract

As the result of a formidable effort, the recent TB epidemic in the United States has abated; however, major questions remain as the risk of TB diminishes. Will we maintain an adequate public health effort not only to prevent another resurgence of TB but also to renew our pursuit of TB elimination? Do we have the will to extend the fight against TB worldwide as the TB threat in the United States declines? What is the best way to incorporate new diagnostic technology into routine practice? What are the best strategies for preventing and treating TB in AIDS patients? From the standpoint of NTM lung diseases, the major challenges are to educate clinicians about the variety and clinical presentation of NTM lung pathogens in order to recognize NTM lung disease as early as possible and to maximize treatment options. Hopefully, we can also improve upon the recent unprecedented progress in treatment regimens for NTM diseases of all types.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9779380     DOI: 10.1016/s0891-5520(05)70200-2

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN: 0891-5520            Impact factor:   5.982


  3 in total

1.  Nontuberculous Mycobacterial Infections of the Lung.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-06       Impact factor: 3.725

2.  Role of complement in Mycobacterium avium pathogenesis: in vivo and in vitro analyses of the host response to infection in the absence of complement component C3.

Authors:  S S Bohlson; J A Strasser; J J Bower; J S Schorey
Journal:  Infect Immun       Date:  2001-12       Impact factor: 3.441

3.  Evaluation of the broth microdilution method using 2,3-diphenyl-5-thienyl-(2)-tetrazolium chloride for rapidly growing mycobacteria susceptibility testing.

Authors:  Sun Min Lee; Jeong man Kim; Joseph Jeong; Young Kil Park; Gill-Han Bai; Eun Yup Lee; Min Ki Lee; Chulhun L Chang
Journal:  J Korean Med Sci       Date:  2007-10       Impact factor: 2.153

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.